ArticleDiabetes technology & therapeutics2022
High-Throughput Multiplex Electrochemiluminescence Assay Applicable to General Population Screening for Type 1 Diabetes and Celiac Disease.
Article in Diabetes technology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Bringing early detection to life: real-world operationalization of a presymptomatic type 1 diabetes screening and monitoring pilot program.BMJ open diabetes research & care · 2026Article
- Interlaboratory Evaluation of Multiplex Autoantibody Assay Performance in the Islet Autoantibody Standardization Program 2024 Workshop.Diabetes care · 2026Article
- Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA.Diabetes · 2026Article
- Stratifying the Rate of Disease Progression by Progression Likelihood Scores in Children and Adolescents With Stage 1 and Stage 2 Type 1 Diabetes in Germany.Diabetes care · 2026Article
- Molecular Portrait of Autoantigens in Type 1 Diabetes.Biomolecules · 2025Review
- Type 1 diabetes risk factors, risk prediction and presymptomatic detection: Evidence and guidance for screening.Diabetes, obesity & metabolism · 2025Review
- IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.Diabetologia · 2025Article
- Article
- Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future.Diabetes · 2025Article
- Enzyme-linked immunosorbent assay of 3 Screen Islet Cell Autoantibody in patients with autoimmune thyroid disease.World journal of diabetes · 2024Article
- A novel, high-performance, low-volume, rapid luciferase immunoprecipitation system (LIPS) assay to detect autoantibodies to zinc transporter 8.Clinical and experimental immunology · 2024Article
- Early autoantibody screening for type 1 diabetes: a Kuwaiti perspective on the advantages of multiplexing chemiluminescent assays.Frontiers in immunology · 2023Article
- A High-throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19.Journal of visualized experiments : JoVE · 2022Article
- Effective assay technologies fit for large-scale population screening of type 1 diabetes.Frontiers in clinical diabetes and healthcare · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.